Merck (MRK), known as MSD outside of the United States and Canada, announced the presentation of results from the Phase 3 Litespark-022 trial evaluating Keytruda, Merck's anti-PD-1 therapy, in combination with Welireg, given in the adjuvant setting, for patients with clear cell renal cell carcinoma following nephrectomy.